This article is more than 5 years old. Information may no longer be current.

Trefoil Therapeutics working with NIH to develop compound for Fuchs' dystrophy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trefoil Therapeutics is working with the National Institutes of Health to complete investigational new drug activities for a compound to treat Fuchs’ endothelial corneal dystrophy, according to a news release.

Trefoil is collaborating with the NIH’s National Center for Advancing Translational Sciences to accelerate the development of the company’s lead compound, TTHX1114.

TTHX1114 is an engineered FGF-1 compound, which displays pharmacodynamic and pharmaceutical properties superior to those of natural FGF-1s in animal models, according to the release.

“We know from speaking with patients and physicians just how significant the unmet medical need [for Fuchs’ dystrophy] is, and now ... we have a path forward to filing an IND with the intention of entering human clinical trials quickly thereafter,” Trefoil CEO David Eveleth, PhD, said in the release. “Our goal is to transform the treatment of Fuchs’ dystrophy by giving patients a pharmaceutical option to regenerate the corneal endothelium and avoid surgery.”